« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6
, Pages
1245-1250
, December 2009
Familial atypical cold urticaria: Description of a new hereditary disease
-
Cutaneous manifestations of 2 affected siblings from family B (A and B) and 1 affected child from family A (C). Fig 2, A, Sixteen-month-old boy after a 5-minute exposure to 5°C atmosphere outdoor expo
Cutaneous manifestations of 2 affected siblings from family B (A and B) and 1 affected child from family A (C). Fig 2, A, Sixteen-month-old boy after a 5-minute exposure to 5°C atmosphere outdoor exposure followed by 5 minutes at room temperature. Fig 2, B, Thirty-four-month-old boy at room temperature for 2 hours, crying. Fig 2, C, Four-year-old girl bathing indoors at room temperature.
-
Negative CSTT result and demonstration of evaporative cooling-induced symptoms. A, CSTT performed for 5 minutes with 5 minutes of rewarming without the development of a wheal. B, Water droplet after 1Negative CSTT result and demonstration of evaporative cooling-induced symptoms. A, CSTT performed for 5 minutes with 5 minutes of rewarming without the development of a wheal. B, Water droplet after 10 minutes of occlusion without any cutaneous manifestations. C, Water droplet after being exposed to compressed air for less than 1 minute with marked erythema and pruritus. Testing with 100% ethanol yielded similar results.
-
Skin biopsy specimens before and after cold challenge stained for mast cell tryptase. A, Patient skin at room temperature for 3 hours with mast cells with visible granules throughout the dermis. B, PaSkin biopsy specimens before and after cold challenge stained for mast cell tryptase. A, Patient skin at room temperature for 3 hours with mast cells with visible granules throughout the dermis. B, Patient skin after 15 minutes of exposure to 5°C with mast cells that appear degranulated throughout the dermis and around vasculature. C, Unrelated normal control skin after 30 minutes of exposure to 5°C.
Supported by National Institutes of Health training grant T32 A107469 and the University of California, San Diego, Department of Pediatrics Opportunity Research Grant.
Disclosure of potential conflict of interest: C. Healy receives honoraria from GlaxoSmithKline and Schering-Plough. H. M. Hoffman is a consultant for Regeneron Pharmaceuticals and Novartis Pharmaceuticals. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)01436-5
doi: 10.1016/j.jaci.2009.09.035
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6
, Pages
1245-1250
, December 2009
